Terms: = Prostate cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Diagnosis
7 results:
1. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
2. prostate cancer dormancy and recurrence.
Cackowski FC; Heath EI
Cancer Lett; 2022 Jan; 524():103-108. PubMed ID: 34624433
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and Biological Features of Neuroendocrine prostate cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
4. Long Noncoding RNA sox2-OT Knockdown Inhibits Proliferation and Metastasis of prostate cancer Cells Through Modulating the miR-452-5p/HMGB3 Axis and Inactivating Wnt/β-Catenin Pathway.
Song X; Wang H; Wu J; Sun Y
Cancer Biother Radiopharm; 2020 Nov; 35(9):682-695. PubMed ID: 32407168
[No Abstract] [Full Text] [Related]
5. prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in prostate cancer.
Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
[TBL] [Abstract] [Full Text] [Related]
6. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC cancer, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract] [Full Text] [Related]
7. cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, sox2 and EZH2.
Matsika A; Srinivasan B; Day C; Mader SA; Kiernan DM; Broomfield A; Fu J; Hooper JD; Kench JG; Samaratunga H
Pathology; 2015 Dec; 47(7):622-8. PubMed ID: 26517640
[TBL] [Abstract] [Full Text] [Related]
